A PYMNTS Company

Australia: Pfizer escapes ACCC’s Lipitor antitrust case

By  |  October 21, 2018

The Australian high court has dismissed the Australian Competition and Consumer Commission’s (ACCC) application for special leave to appeal the Pfizer Australia ruling by the full federal court decision that the drug maker used its market dominance to reduce competition for its cholesterol-lowering drug Lipitor.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to the charges, Pfizer was accused to have abused its market dominance by providing huge discounts and rebates to pharmacies for Lipitor.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Pharmacies allegedly purchased large quantities of Lipitor and agreed to reduce re-supply of competing products.

    The federal court found that the company took advantage of its market dominance as the patent holder of atorvastatin; however, it refused to accept the Commission’s argument that the company had acted in a way to reduce or stop competition.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.